David M. Hyman

Also affiliated with WinnMed, Mayo Clinic in Florida

Biochemistry, Genetics and Molecular BiologyMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

1in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Data from Natural History and Characteristics of ERBB2-mutated Hormone Receptor–positive Metastatic Breast Cancer: A Multi-institutional Retrospective Case–control Study from AACR Project GENIE

(2023)10.1158/1078-0432.c.6531065.v1

Top 100%

0DataRank

Top 100%0 citations

Sheau‐Chiann Chen, Thomas Stricker, David M. Hyman, Natalie Blauvelt, Philippe L. Bédard +18 more

Papers

Driven by 21 papers — median percentile 0. Top paper: “Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with AKT1 E17K-Mutant, ER-Positive Metastatic Breast Cancer”.

Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with AKT1 E17K-Mutant, ER-Positive Metastatic Breast Cancer

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-19-3953

N/A

3.2DataRank · unranked

108 citations

Kenji Tamura, Mafalda Oliveira, Eva Ciruelos, Ingrid A. Mayer, Marie‐Paule Sablin +23 more

Characteristics and Outcome of AKT1 E17K-Mutant Breast Cancer Defined through AACR Project GENIE, a Clinicogenomic Registry

Cancer Discovery(2020)10.1158/2159-8290.cd-19-1209

N/A

2.3DataRank · unranked

51 citations

Qin Zhou, Bastien Nguyen, Celeste Yu, Eva M. Lepisto, Mónica Arnedos +27 more

Identification of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer by Using HER2-targeted 89Zr-Pertuzumab PET/CT

Radiology(2020)10.1148/radiol.2020192828

N/A

2.1DataRank · unranked

70 citations

Jorge A. Carrasquillo, Christopher C. Riedl, Randy Yeh, Vaios Hatzoglou, Dara S. Ross +7 more

Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancer

npj Breast Cancer(2021)10.1038/s41523-021-00251-7

N/A

1.4DataRank · unranked

36 citations

Gerald Batist, Funda Meric‐Bernstam, Peter Kabos, Iben Spanggaard, Aňa Lluch +22 more

Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients

Nature Medicine(2017)10.1038/nm.4333

N/A

1.2DataRank · unranked

3490 citations

Ryma Benayed, Ronak H Shah, Aijazuddin Syed, Sumit Middha, Hyunjae R. Kim +116 more

Characterization and management of ERK inhibitor associated dermatologic adverse events: analysis from a nonrandomized trial of ulixertinib for advanced cancers

Investigational New Drugs(2021)10.1007/s10637-020-01035-9

N/A

1.2DataRank · unranked

32 citations

D. Liu, Michael Offin, Cecilia Lezcano, Jean Torrisi, Sheldon L. Brownstein +13 more

AKT mutant allele-specific activation dictates pharmacologic sensitivities

Nature Communications(2022)10.1038/s41467-022-29638-1

N/A

1.2DataRank · unranked

36 citations

Tambudzai Shamu, Alexander N. Gorelick, Matthew T. Chang, Debyani Chakravarty, Elena I. Gavrila +14 more

Cancer therapy shapes the fitness landscape of clonal hematopoiesis

Nature Genetics(2020)10.1038/s41588-020-00710-0

N/A

0.993DataRank · unranked

750 citations

Ryan Ptashkin, Teng Gao, Lior Z. Braunstein, Sean M. Devlin, Daniel J. Kelly +59 more

Pan-Cancer Efficacy of Vemurafenib in BRAF V600-Mutant Non-Melanoma Cancers

Cancer Discovery(2020)10.1158/2159-8290.cd-19-1265

N/A

0.727DataRank · unranked

126 citations

Igor Puzanov, Jean‐Yves Blay, Ian Chau, A. Craig Lockhart, Noopur Raje +11 more

Neurologic and oncologic features of Erdheim–Chester disease: a 30-patient series

Neuro-Oncology(2020)10.1093/neuonc/noaa008

N/A

0.617DataRank · unranked

60 citations

Vaios Hatzoglou, Gary A. Ulaner, Raajit K. Rampal, David M. Hyman, Omar Abdel-Wahab +10 more

Discovery through clinical sequencing in oncology

Nature Cancer(2020)10.1038/s43018-020-0100-0

N/A

0.550DataRank · unranked

38 citations

Alison M. Schram, David M. Hyman, Barry S. Taylor, Mark T.A. Donoghue

Utility of Serial cfDNA NGS for Prospective Genomic Analysis of Patients on a Phase I Basket Study

JCO Precision Oncology(2021)10.1200/po.20.00184

N/A

0.365DataRank · unranked

5 citations

Jonathan Reichel, Jiabin Tang, Juber Patel, Fanli Meng, Duygu Selcuklu +15 more

Natural History and Characteristics of ERBB2 -mutated Hormone Receptor–positive Metastatic Breast Cancer: A Multi-institutional Retrospective Case–control Study from AACR Project GENIE

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-21-0885

N/A

0DataRank · unranked

3 citations

Sheau‐Chiann Chen, Thomas Stricker, David M. Hyman, Natalie Blauvelt, Philippe L. Bédard +18 more

Genomic Landscape of Uterine Sarcomas Defined Through Prospective Clinical Sequencing

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-19-3959

N/A

0DataRank · unranked

119 citations

Shweta S. Chavan, David B. Solit, Rajmohan Murali, Robert A. Soslow, Sarah Chiang +9 more

Data from Natural History and Characteristics of ERBB2-mutated Hormone Receptor–positive Metastatic Breast Cancer: A Multi-institutional Retrospective Case–control Study from AACR Project GENIE

(2023)10.1158/1078-0432.c.6531065.v1

Top 100%

0DataRank

Top 100%0 citations

Sheau‐Chiann Chen, Thomas Stricker, David M. Hyman, Natalie Blauvelt, Philippe L. Bédard +18 more

Characterization of on-target adverse events caused by TRK inhibitor therapy

Annals of Oncology(2020)10.1016/j.annonc.2020.05.006

N/A

0DataRank · unranked

86 citations

James Flory, Andrew Lin, Michael Offin, Christina J. Falcon, Yonina R. Murciano‐Goroff +16 more

TRK xDFG Mutations Trigger a Sensitivity Switch from Type I to II Kinase Inhibitors

Cancer Discovery(2020)10.1158/2159-8290.cd-20-0571

N/A

0DataRank · unranked

70 citations

Ji Eun Lee, Srinivasaraghavan Kannan, Alison M. Schram, Helen Won, Sophie Shifman +29 more

HER2-Mediated Internalization of Cytotoxic Agents in ERBB2 Amplified or Mutant Lung Cancers

Cancer Discovery(2020)10.1158/2159-8290.cd-20-0215

N/A

0DataRank · unranked

293 citations

Flavia Michelini, Sandra Misale, Emiliano Cocco, Laura Baldino, Yanyan Cai +44 more

Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with PIK3CA -Mutant Cancers

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-20-2657

N/A

0DataRank · unranked

39 citations

Matthew T. Chang, Dejan Juric, Cristina Saura, Valentina Gambardella, Anton Melnyk +16 more

Enrichment of kinase fusions in ESR1 wild-type, metastatic breast cancer revealed by a systematic analysis of 4854 patients

Annals of Oncology(2020)10.1016/j.annonc.2020.04.008

N/A

0DataRank · unranked

33 citations

Bo Liu, Alison M. Schram, Pedram Razavi, Stephen M. Lagana, Y. Zhang +10 more

The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers

Nature Communications(2022)10.1038/s41467-022-28848-x

N/A

0DataRank · unranked

114 citations

Helen Won, Youyun Zheng, Emiliano Cocco, Duygu Selcuklu, Yixiao Gong +27 more

David M. Hyman

Indexed papers

Top data-sharing exemplar

Papers